• Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approach
  • Lead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a clinically validated dual-targeting CD19/BCMA CAR construct to support broad B-cell lineage reset across multiple indications
  • First investigator-initiated trial expected to enroll approximately 10 patients with nervous system autoimmune diseases, including MG and MS, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027

     

BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell ("CAR-T") product candidates, today announced details of its next-generation in vivo CAR-T platform. The company plans to advance TPST-4003, its lead in vivo CAR-T product candidate, into a first investigator-initiated clinical trial in patients with nervous system autoimmune diseases, initially focusing on myasthenia gravis ("MG") and multiple sclerosis ("MS"). The study is expected to enroll approximately 10 patients, with first patient dosing anticipated in the fourth quarter of 2026.